title: Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study.
abstract: OBJECTIVE
  Mebendazole is an anthelmintic that is commonly needed in women of reproductive age. Its use in pregnancy is a reason for concern for women and their health care providers. The purpose of this study was to examine the fetal safety of mebendazole.
  
  
  METHODS
  The Israeli Teratogen Information Service prospectively collected and followed 192 pregnancies exposed to mebendazole in pregnancy, 71.5% of whom had first-trimester exposure. Pregnancy outcome was compared with that of a matched control group, who were counseled for nonteratogenic exposure.
  
  
  RESULTS
  There was no increase in the rate of major malformations between the groups (5/150 pregnancies [3.3%; mebendazole] vs 3/175 pregnancies [1.7%; nonteratogenic control subjects]; P =.478). There was a higher rate of elective terminations of pregnancy in the exposed group compared with the control group (22/192 pregnancies [11.5%; mebendazole] vs 3/192 pregnancies [1.6% [nonteratogenic control subjects]; P =.000).
  
  
  CONCLUSIONS
  This study suggests that mebendazole does not represent a major teratogenic risk in humans when it is used in the doses that are used commonly for pinworm (Enterobius vermicularis) infestation.
authors.affiliation: Israeli Teratogen Information Service, Israel Ministry of Health, Jerusalem, Israel.
authors.forename: Orna
authors.initials: O
authors.lastname: Diav-Citrin
authors.forename: Svetlana
authors.initials: S
authors.lastname: Shechtman
authors.forename: Judy
authors.initials: J
authors.lastname: Arnon
authors.forename: Israela
authors.initials: I
authors.lastname: Lubart
authors.forename: Asher
authors.initials: A
authors.lastname: Ornoy
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000028:Abortion, Induced / Q000706:statistics & numerical data; D000328:Adult; D000969:Antinematodal Agents / Q000009:adverse effects*; D001724:Birth Weight; D015331:Cohort Studies; D017229:Enterobiasis / Q000188:drug therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D008431:Maternal-Fetal Exchange; D008463:Mebendazole / Q000008:administration & dosage / Q000009:adverse effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000969:Antinematodal Agents; D008463:Mebendazole